NTA Sample Clauses

NTA. Assuming that the Proposed Transaction had been effected on 31 December 2014, being the end of the most recently completed financial year of the Group for which financial statements are publicly available, the financial effects on the NTA per share of the Group as at 31 December 2014 would be as follows: NTA (S$ million) 1,772.9 1,888.2 Number of issued stock units (‘000) 615,357 (1) 615,357 (1) NTA per stock unit (S$) 2.88 3.07 (1) Based on total number of issued stock units excluding 21,712,000 stock units held by WBL.
Sample 1Sample 2
AutoNDA by SimpleDocs
NTA. For illustrative purposes only and assuming the Transaction and the placement of 32,000,000 new Shares had been completed at the end of FY2011, the estimated financial effects of the Transaction and Placement on the consolidated net tangible asset of the Group ("NTA") as at the end of FY2011 are as follows:- As at 30 June 2011 Assuming completion of the Placement(1) as at the end of FY2011 Assuming completion of the Transaction and Placement as at the end of FY2011 NTA (S$'000) 23,798 30,158 27,454(2) Number of Shares ('000) 162,500 194,500 194,500 NTA per Share (cents) 14.6 15.5 14.1 Notes: (1) Net proceeds from issuance and allotment of 32,000,000 new Shares at S$0.20 per Share amounting to S$6,360,000. (2) After deducting provisional goodwill arising from the acquisition of HCCM amounting to approximately S$2,679,000 (equivalent to approximately RMB 13,115,000) and expenses of estimated acquisition- related costs of S$25,000. Provisional goodwill is the difference between consideration paid for 29.4% of registered and paid-up capital of HCCM amounting to S$4,392,000 (equivalent to RMB 21,500,000) and the Company’s 29.4% share of adjusted net assets of HCCM as at 30 November 2011 amounting to S$1,713,000 (equivalent to RMB 8,385,000). Foreign currency exchange rate of S$1:RMB4.895 on 22 December 2011 is applied.
Sample 1Sample 2
NTA. Between the date of this Agreement and the end of the Offer Period, the NTA per LRF Unit does not fall below $0.765.
Sample 1
NTA. Scenario 1: For illustrative purposes and assuming the Loan Shares and Interest Shares had been allotted and issued at the end of FY2014, with S$10.0 million of Loan being converted at Loan Conversion Price of S$0.21 per Loan Share, and 1 time Accrued Interest being converted at minimum Interest Conversion Price of S$0.11. As at 31 March 2014 Loan Shares Interest Shares Assuming the allotment and issue of all the Loan Shares and Interest Shares is at the end of FY2014 NTA (S$’000) 61,533 10,000 71,533 Number of Shares (‘000) 773,149 47,619 9,091 829,859 NTA per Share (cents) 7.96 21.00 8.62
Sample 1
NTA. For the purposes of illustration only and assuming the Transaction had been completed at the end of FY2012, the estimated financial effects of the Transaction on the consolidated NTA of the Hafary Group as at the end of FY2012 are as follows: As at 30 June 2012 Assuming completion of the Transaction as at the end of FY 2012 NTA (S$’000) 30,497 29,684 (1) Number of shares (‘000) 194,500 194,500
Sample 1
NTA. Assuming that the Proposed Settlement had been effected on 31 December 2021 (being the end of the most recently completed financial year ended 31 December 2021), the effects on the NTA per share of the Group would be as follows: Before the Proposed Settlement After the transfer of the Contra Properties(1) After the transfer of the Contra Properties and Escrow Properties (assuming the enforcement of all Escrow Property 1 On 13 July 2021, the Company announced that its financial year end has changed from 30 June to 31 December (the “Change of FYE”). As a result of the Change of FYE, the last financial year of the Company ended on 31 December 2021 (being the first financial year affected by the Change of FYE) covered an 18- month period from 1 July 2020 to 31 December 2021. Thereafter, the financial year of the Company would commence on 1 January each year, and end on 31 December each year. Transfer Documents)(1) NTA (RM) 71,936,711 77,394,783 81,602,734 Number of shares 1,869,434,303 1,869,434,303 1,869,434,303 NTA per ordinary share (RM cents) 3.85 4.14 4.37
Sample 1

Related to NTA

  • meminta nasihat daripada Pihak Xxxxxx dalam semua perkara berkenaan dengan jualan lelongan, termasuk Syarat-syarat Jualan (iii) membuat carian Hakmilik Xxxxx xxxxxx rasmi di Pejabat Tanah xxx/atau xxxx-xxxx Pihak-pihak Berkuasa yang berkenaan xxx (iv) membuat pertanyaan dengan Pihak Berkuasa yang berkenaan samada jualan ini terbuka kepada semua bangsa atau kaum Bumiputra Warganegara Malaysia sahaja atau melayu sahaja xxx juga mengenai persetujuan untuk jualan ini sebelum jualan lelong.Penawar yang berjaya ("Pembeli") dikehendaki dengan segera memohon xxx mendapatkan kebenaran pindahmilik (jika ada) daripada Pihak Pemaju xxx/atau Pihak Tuanpunya xxx/atau Pihak Berkuasa Negeri atau badan-badan berkenaan (v) memeriksa xxx memastikan samada jualan ini dikenakan cukai. HAKMILIK : Hakmilik strata bagi hartanah ini masih belum dikeluarkan HAKMILIK INDUK / NO. LOT : Pajakan Negeri 35263, Lot No.29096 MUKIM/DAERAH/NEGERI : Setapak / Kuala Lumpur / Wilayah Persekutuan Kuala Lumpur PEGANGAN : Pajakan selama 82-tahun berakhir pada 08/08/2085 KELUASAN LANTAI : 81.104 meter persegi ( 873 kaki persegi ) PEMAJU/PENJUAL : Mega Planner Jaya Sdn Bhd (326287-W)(Dalam Likuidasi) TUANPUNYA : Datuk Bandar Kuala Lumpur PEMBELI : Xxxxxxxx Bin Xxxxx @ Xxxx BEBANAN : Diserahhak kepada RHB Bank Berhad [196501000373 (6171-M)] Hartanah tersebut terletak di tingkat 9 pada bangunan apartment 14-tingkat terletak di Melati Impian Apartment, Setapak Fasa 1, Kuala Lumpur. Hartanah tersebut adalah sebuah unit apartment 3 xxxxx dikenali sebaga Xxxxx Pemaju No. 9, Tingkat No.9, Pembangunan dikenali sebagai Melati Impian Apartment Setapak Fasa 1, Kuala Lumpur xxx mempunyai alamat surat-xxxxxxxx xx Xxxx Xx. 0-0, Xxxxxx Impian Apartment, Xxxxx 0/00X, Xxxxx Xxxxxx, 00000 Xxxxx Xxxxxx, Xxxxxxx Xxxxxxxxxxx Xxxxx Xxxxxx. Harta ini dijual “keadaan seperti mana sediada” dengan harga rizab sebanyak RM 300,000.00 (RINGGIT MALAYSIA: TIGA RATUS RIBU SAHAJA) xxx tertakluk kepada syarat-syarat Jualan xxx melalui penyerahan hakkan dari Pemegang Serahak, tertakluk kepada kelulusan di perolehi oleh pihak Pembeli daripada pihak berkuasa, jika ada, termasuk semua terma, syarat xxx perjanjian yang dikenakan xxx mungkin dikenakan oleh Pihak Berkuasa yang berkenaan. Pembeli bertanggungjawab sepenuhnya untuk memperolehi xxx mematuhi syarat-syarat berkenaan daripada Pihak Berkuasa yang berkenaan, jika ada xxx semua xxx xxx perbelanjaan ditanggung xxx dibayar oleh Xxxxx Xxxxxxx.Pembeli atas talian (online) juga tertakluk kepada terma-terma xxx syarat-syarat terkandung dalam xxx.xxxxxxxxxxxxxxxx.xxx Pembeli yang berminat adalah dikehendaki mendeposit kepada Pelelong 10% daripada harga rizab dalam bentuk Bank Draf atau Cashier’s Order di atas nama RHB Bank Berhad sebelum lelongan awam xxx xxxx xxxx xxxxxx hendaklah dibayar dalam tempoh sembilan puluh (90) hari dari tarikh lelongan kepada RHB Bank Berhad melalui Bank Draf / XXXXXX. Butir-butir pembayaran melalui XXXXXX, xxxx berhubung dengan Tetuan Zahrin Emrad & Sujaihah. Untuk maklumat lanjut, xxxx berhubung dengan TETUAN ZAHRIN EMRAD & SUJIAHAH, yang beralamat di Suite 10.3, 10th Floor, Xxx Xxxx Building, Xx.00, Xxxxx Xxxx Xxxxxx, 00000 Xxxxx Xxxxxx. Tel: 00-0000 0000 / Fax: 00-0000 0000. [ Ruj: ZES/ZHR/RHB-FC/16250-17/0614-pae ], peguamcara bagi pihak pemegang xxxxx xxx atau pelelong yang tersebut dibawah.

  • Conhecimento da Lingua O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da língua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condições estabelecidas no Plano e no Acordo de Atribuição (“Agreement” xx xxxxxx).

  • S&P Standard & Poor’s Ratings Services, a division of The XxXxxx-Xxxx Companies, Inc., or its successor.

  • S.A 59:1-1 et seq.), the New Jersey Contractual Liability Act (N.J.

  • Consentement Relatif à la Langue Utilisée Les parties reconnaissent avoir exigé que cette convention («Agreement») soit rédigée en anglais, ainsi que tous les documents, avis et procédures judiciaires, éxécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à la présente.

  • WSIB & LTD An Employee who is receiving benefits under the Workplace Safety and Insurance Act, or under an LTD plan, is not entitled to benefits under a school board’s sick leave and short-term disability plan for the same condition unless the employee is on a graduated return to work program then WSIB/LTD remains the first payor. For clarity, where an employee is receiving partial benefits under WSIB/LTD, they may be entitled to receive benefits under the sick leave plan, subject to the circumstances of the specific situation. During the interim period from the date of the injury/incident or illness to the date of the approval by the WSIB/LTD of the claim, the employee may access sick leave and short-term leave and disability coverage. A reconciliation of sick leave deductions made and payments provided, will be undertaken by the school board once the WSIB/LTD has adjudicated and approved the claim. In the event that the WSIB/LTD does not approve the claim, the school board shall deal with the absence consistent with the terms of the sick leave and short-term leave and disability plans.

  • CUKAI Jualan hartanah tersebut akan dikenakan cukai berdasarkan mana-mana Akta terkini atau selepasnya yang dikuatkuasa oleh Kerajaan Malaysia yang mana berkenaan. Sebarang tunggakan caj perkhidmatan atau penyelenggaraan tanpa faedah penalti lewat (jika ada) yang tertunggak xxx perlu dibayar kepada mana-mana pihak berkuasa yang berkenaan xxx/atau pihak Pemaju akan ditanggung oleh pihak Pemegang Xxxxx Xxx/Pemberi Pinjaman setakat tarikh jualan lelongan hartanah tersebut (tertakluk kepada maksimum 10% daripada harga rizab) yang akan dibayar daripada harga pembelian, dengan syarat bahawa Pemegang Xxxxx Xxx/Pemberi Pinjaman menerima xxx xxxx terperinci untuk caj perkhidmatan penyelenggaraan xxx penyata akaun yang dikeluarkan oleh pihak berkuasa xxx/atau pemaju yang berkaitan daripada Pembeli dalam tempoh sembilan puluh (90) hari dari tarikh jualan xxx jika gagal pembeli tidak akan layak untuk apa-apa pembayaran, xxx sebarang jumlah tertunggak yang perlu dibayar selepas tarikh jualan lelongan hartanah tersebut hendaklah ditanggung oleh pembeli.

  • HARGA RIZAB Hartanah tersebut akan dijual “Dalam Keadaan Xxxxx Xxx” xxx tertakluk kepada satu harga rizab sebanyak RM669,000.00 (RINGGIT MALAYSIA: ENAM RATUS XXX ENAM PULUH SEMBILAN RIBU SAHAJA) xxx Syarat-syarat Jualan xxx tertakluk kepada kebenaran yang diperolehi oleh Pembeli dari Pemaju/Pemilik Tanah xxx Pihak Berkuasa yang lain, jika ada. DEPOSIT:- Semua penawar yang ingin membuat tawaran dikehendaki mendepositkan kepada Pelelong, sebelum lelongan 10% daripada harga rizab secara BANK DERAF sahaja atas nama BANK KERJASAMA RAKYAT MALAYSIA BERHAD xxx xxxx xxxx xxxxxx hendaklah dijelaskan dalam tempoh Sembilan Xxxxx (00) Hari. Bagi penawar atas talian sila rujuk Terma xxx Syarat serta cara pembayaran deposit di xxx.xxxxxxxxxxxxxxx.xxx Nota: Butir-butir hartanah adalah berdasar Laporan Penilaian xxx perjanjian-perjanjian pembiayaan yang mana berdasarkan pengetahuan kami adalah benar. Walaubagaimanapun pembida hendaklah membuat xxxxxx xxxxx atas hakmilik induk di pejabat tanah xxx/atau pihak berkuasa berkenaan. Perjanjian ini tidak akan menjadi terbatal sekiranya terdapat perbezaan berkenaan butir-butir hartanah Untuk mendapatkan butir-butir selanjutnya, xxxx berhubung dengan Tetuan Suhaimi Yahya & Co Peguamcara bagi Pihak Pemegang Serahhak/Bank di Xx. 0-0, Xxxxx Xxxxxx Xxxxxx 00, Wangsa Link, Xxxxxx Xxxx, 00000 Xxxxx Xxxxxx. (Ruj No. SY/BKRM(PJS)/LIT/010/2021/L) Tel No: 00-00000000, Fax No. 00-00000000, atau Pelelong yang tersebut di bawah ini:- Suite B-15-03, Tingkat 15, Blok B, Megan Avenue 2, (Pelelong Berlesen) 00, Xxxxx Xxx Xxxx Xxxx, 50450 Kuala Lumpur TEL NO: 00-0000000, H/P NO: 000-0000000/000-0000000 FAX NO: 00-0000000 E-mail: xxxxxxxxxxxxxxx@xxxxx.xxx Web site : xxx.xxxxxxxxxxxxxxx.xxx Rujukan kami : EZ/LACA/BKRMB/212/2021/MNS/mas

  • DUŠEVNÍ VLASTNICTVÍ a) The Institution and the Investigator acknowledge and agree that the Sponsor shall have exclusive ownership rights to all Study Data, Study results, information, improvements, developments, discoveries, inventions, work, know-how and other rights (whether or not patentable), created, developed, and/or reduced to practice as a result of or in connection with the conduct of the Study and/or the use of the Study Drug or the Confidential Information, together with all intellectual property rights (existing and future) relating thereto (“Intellectual Property”) conceived by the Institution or the Investigator or Study Personnel, solely or jointly with others as a result of work done under this Agreement, to the widest extent possible under applicable law. The Institution and the Investigator shall promptly disclose in writing to PSI and the Sponsor all Intellectual Property made or reduced to practice by the Institution, the Investigator and/or the Study Personnel related to the Study. At the Sponsor's request, the Institution and the Investigator shall cause all rights titles and interests in and to any such Intellectual Property to be assigned to the Sponsor without additional compensation and provide reasonable assistance to obtain patents, including causing the execution of any invention assignment or other documents. b) All parties to this Agreement and Sponsor shall retain all right, title and interest in any Intellectual Property that was owned by such party or Sponsor prior to or apart from the commencement of this Agreement. No a) Zdravotnické zařízení a Hlavní zkoušející uznávají a souhlasí, že Zadavatel bude mít výhradní vlastnická práva ke všem Studijním údajům, výsledkům Studie, informacím, vylepšením, na vývoj, k objevům, vynálezům, dílům, know-how a dalším právům (ať už patentovatelným či nikoli), vytvořeným, vyvinutým, a/nebo uvedeným do praxe v důsledku nebo v souvislosti s prováděním Studie, a/nebo používáním Studijního léku nebo Důvěrných informací společně s právy duševního vlastnictví (stávajícími i budoucími) s nimi souvisejícími (dále jen „Duševní vlastnictví“), které vytvořilo Zdravotnické zařízení, Hlavní zkoušející nebo Studijní personál, samostatně nebo společně s ostatními jako výsledek práce prováděné na základě této Smlouvy, a to v největším možném rozsahu povoleném příslušnými zákonnými předpisy. Zdravotnické zařízení a Hlavní zkoušející budou neprodleně písemně informovat PSI a Zadavatele o veškerém Duševním vlastnictví vytvořeném nebo uvedeném do praxe Zdravotnickým zařízením, Hlavním zkoušejícím a/nebo Studijním personálem v souvislosti se Studií. Na žádost Zadavatele zajistí Zdravotnické zařízení a Hlavní zkoušející převod veškerých práv a zájmů týkajících se Duševního vlastnictví na Zadavatele bez další odměny a poskytnou přiměřenou součinnost k získání patentu včetně zajištění podpisu dokumentů k převodu objevu nebo jiných dokumentů. b) Všechny strany této Smlouvy a Zadavatel si i nadále ponechají veškerá práva, nároky a podíly na jakémkoli Duševním vlastnictví, které daná strana nebo Zadavatel vlastnili před začátkem platnosti této Smlouvy nebo na které license grant or assignment, express or implied, by estoppel or otherwise, is intended by, or shall be inferred from, this Agreement except to the extent necessary for each party to fulfill its obligations under this Agreement or otherwise give effect to this Agreement.

  • Sub-licensing CytRx shall be entitled to grant sub-licences of its rights under the terms and conditions of Clause 2.1 of this Agreement to any person, provided that: (a) the sub-licence shall include performance and financial obligations on the sub-licensee which are at least equivalent to the obligations on CytRx under this Agreement; (b) the sub-licence shall continue following the termination of this Agreement for any reason as a licence between ICIL and the sub-licensee pursuant to clause 14.5.2, provided that if the royalties and other consideration provided for in the sub-licence are less that that provided for in this Agreement such royalties or other consideration shall be increased to be the same as provided for in this Agreement and further provided that the sub-licensee agrees in writing to such new financial terms and to the substitution of CytRx by ICIL; (c) within thirty (30) days of the grant of any sub-licence CytRx shall provide to ICIL a summary of the material terms of the sub-licence and a written agreement from the sub-licensee to be bound by the provisions of this Agreement to the extent applicable; (d) except in the case of the continuation of the licence pursuant to Clause 2.5(b) CytRx shall be responsible for any breach of the sub-licence by the sub-licensee, as if the breach had been that of CytRx under this Agreement, and CytRx shall indemnify ICIL against any loss, damages, costs, claims or expenses which are awarded against or suffered by ICIL as a result of any such breach by the sub-licensee; and (e) no sub-licence shall carry any right to sub-sub-licence all of the rights granted to CytRx under this Agreement without the consent of ICIL (such consent not to be unreasonably withheld) save that a sub-licence can be sub-licensed for the purposes of manufacture or co-marketing without the consent of ICIL.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!